Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Insulin degludec significantly improves blood sugar control compared with insulin glargine, data show

Using electronic health record data, researchers found that HbA1c levels declined by 1.5% among insulin degludec-treated patients compared with 1.2% in those treated with insulin glargine U300 over six months.

Degludec insulin molecule

Source: Science Photo Library

In a large study using real-world data, researchers found that insulin degludec (pictured) reduces the rate of hypoglycaemia compared with insulin glargine

Treatment with insulin degludec (Tresiba; Novo Nordisk) in type 2 diabetes mellitus (T2DM) improves glycaemic control and leads to fewer hypoglycaemic episodes compared with insulin glargine, according to results from a study of real-world data, presented at the American Diabetes Association Scientific Sessions in Orlando, Florida, on 25 June 2018[1].

Using electronic health records, researchers used data from 2,028 patients with T2DM who had their treatment intensified with insulin degludec injection and compared them with an equal number of patients whose treatment was intensified with insulin glargine U300 (Toujeo; Sanofi), a basal insulin approved by the European Commission in January 2013.

Between baseline and six months, HbA1c levels declined by an average of 1.5% in the degludec group, compared with 1.2% in the glargine group — a significant difference.

Additionally, the rate of reported hypoglycaemic episodes was 30% lower in the degludec-treated patients compared with glargine-treated patients. Glargine-treated patients were also 37% more likely to discontinue their therapy than degludec-treated patients, the researchers found.

Data from clinical trials indicate that insulin degludec reduces the rate of hypoglycaemia compared with insulin glargine, but the researchers said this is the largest study using real-world data to demonstrate this.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2018.20205369

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.